ExodusPoint Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

ExodusPoint Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,699	Closed	-$326K	–	2070
2023 Q4	$326K	Sell	7,699 -34,535	-82%	-$992K	﹤0.01%	1158
2023 Q3	$922K	Buy	42,234 +26,989	+177%	+$675K	0.01%	990
2023 Q2	$485K	Buy	+15,245	New	+$468K	﹤0.01%	1373
2021 Q2	–	Sell	-88,092	Closed	-$1.21M	–	2923
2021 Q1	$1.21M	Buy	88,092 +38,100	+76%	+$558K	0.02%	808
2020 Q4	$829K	Buy	+49,992	New	+$649K	0.01%	964

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ExodusPoint Capital Management's CERE Position: Q1 2024 in Review

ExodusPoint Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 7,699 shares — an estimated $326K sold.

ExodusPoint Capital Management first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $1.21M in Q1 2021. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

ExodusPoint Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 7,699 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $326K.
ExodusPoint Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
ExodusPoint Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.21M in Q1 2021.
210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on ExodusPoint Capital Management's 13F filing for Q1 2024, filed 14 May 2024.